文献速递临床试验与 GCP基础与转化研究

术前免疫营养对膀胱切除术术后并发症与免疫反应的作用:多中心随机对照试验(INCyst试验)方案

The role of preoperative immunonutrition on morbidity and immune response after cystectomy: protocol of a multicenter randomized controlled trial (INCyst Trial).
PubMed 文献 · Trials · 2024-10-17

本研究为随机、多中心、对照、实用性、平行组比较研究,计划于2023年4月至2026年6月纳入232例择期根治性或单纯性膀胱切除术患者。患者随机接受术前7天免疫营养(Oral Impact®)或标准治疗,随访90天,评估30天和90天并发症与死亡率,并探索免疫与微生物组特征对免疫营养效果的预测作用。

要点

  • 术前7天免疫营养对比标准治疗,评估膀胱切除术后30天和90天并发症与死亡率。
  • 计划纳入232例,2023年4月至2026年6月,在洛桑、伯尔尼和里维埃拉-沙布莱三个中心进行。
  • 探索性结局包括免疫适应度(流感疫苗接种反应)、微生物组和精氨酸琥珀酸合成酶1表达。

核心结论

  • INCyst研究将挑战术前免疫营养在膀胱切除术患者中的附加价值,评估其对术后并发症和死亡率发生的影响。
  • 该研究还将提供关于宿主免疫反应和微生物组组成的宝贵数据。

研究设计与样本

  • 随机、多中心、对照、实用性、平行组比较研究,由瑞士国家科学基金会支持。
  • 计划于2023年4月至2026年6月纳入232例患者,参与中心为洛桑、伯尔尼和里维埃拉-沙布莱三个中心。
  • 所有接受择期根治性和单纯性膀胱切除术的患者随机接受术前7天免疫营养(Oral Impact®,雀巢,瑞士)或标准治疗(对照组),术后随访90天。

关键数值与推荐

  • 主要目的是评估免疫营养对膀胱切除术后30天和90天并发症和死亡率的影响。
  • 探索性结局包括免疫和微生物组特征对免疫营养效果的预测。
  • 在洛桑治疗的患者中收集血液、血清、尿液和粪便样本,并接种流感疫苗以追踪疫苗特异性免疫反应。
  • 将分析微生物组和精氨酸琥珀酸合成酶1表达作为潜在生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cancer, malnutrition, and surgery negatively impact patient's immune system. Despite standardized surgical technique and the development of new perioperative care protocols, morbidity after cystectomy remains a serious challenge for urologists. Most common postoperative complications, such as infections and ileus, often lead to longer length of stay and worse survival. The immune system and its interaction with the gut microbiota play a pivotal role in cancer immunosurveillance and in patient's response to surgical stress. Malnutrition has been identified as an independent and modifiable risk factor for both mortality and morbidity. Immunonutrition (IN) may improve the nutritional status, immunological function, and clinical outcome of surgical patients. Aims of the study are (1) to evaluate the impact of IN on morbidity and mortality at 30 and 90 days after cystectomy and (2) to determine immune and microbiota signature that would predict IN effect. METHODS: This is a randomized, multicentric, controlled, pragmatic, parallel-group comparative study, supported by the Swiss National Science Foundation. A total of 232 patients is planned to be enrolled between April 2023 and June 2026. Three participating centers (Lausanne, Bern, and Riviera-Chablais) have been selected. All patients undergoing elective radical and simple cystectomy will be randomly assigned to receive 7 days of preoperative IN (Oral Impact®, Nestlé, Switzerland) versus standard of care (control group) and followed for 90 days after surgery. For the exploratory outcomes, blood, serum, urine, and stool samples will be collected in patients treated at Lausanne. In order to determine the impact of IN on immune fitness, patients enrolled at Lausanne will be vaccinated against influenza and the establishment of the vaccine-specific immune response will be followed. Analysis of the microbiota and expression of argininosuccinate synthetase 1 as potential biomarker will also be performed. DISCUSSION AND CONCLUSION: Strengths of the INCyst study include the randomized, multicenter, prospective design, the large number of patients studied, and the translational investigation. This study will challenge the added value of preoperative IN in patients undergoing cystectomy, assessing the clinical effect of IN on the onset of postoperative morbidity and mortality after cystectomy. Furthermore, it will provide invaluable data on the host immune response and microbiota composition. TRIAL REGISTRATION: ClinicalTrials.gov NCT05726786. Registered on March 9, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Derré L, Crettenand F, Grilo N, et al. The role of preoperative immunonutrition on morbidity and immune response after cystectomy: protocol of a multicenter randomized controlled trial (INCyst Trial). Trials. 2024. PMID: 39415282. doi:10.1186/s13063-024-08536-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。